Document is current
Any future updates will be listed below
-
Authors
Esparragosa Vázquez, Inés https://orcid.org/0000-0001-6823-7088
Fortes de la Torre, Inmaculada
Hilario, Amaya
Iglesias Lozano, Irene
Hernández-Laín, Aurelio
Pineda, Estela
Sepúlveda Sánchez, Juan Manuel
Vaz-Salgado, Maria Angeles
-
Funding
Funding for this research was provided by:
Servier
- License Information
-
More Information
Article History
Received: 5 February 2026
Accepted: 14 March 2026
First Online: 31 March 2026
Declarations
:
: Inés Esparragosa Vázquez: consulting services as a member of the Glioma Working Group, Salud Harmon-Servier. Inmaculada Fortes de la Torre: expenses for attending meetings sponsored by Servier. Amaya Hilario: consulting services as a member of the Glioma Working Group, Salud Harmon-Servier. Estela Pineda: advisory and consulting for Servier and Novocure; advisory for GSK and AstraZeneca. Juan Manuel Sepúlveda Sánchez: consulting and presentation fees from Servier. María Ángeles Vaz-Salgado: advisory and speaker fees from Novocure and Servier. Irene Iglesias Lozano: none declared. Aurelio Hernández-Laín: none declared.
: This study involved only expert panelists who volunteered for the Delphi process. No patient data were used. Participation implied informed consent, and formal ethical approval was not required.
